Home » Bruna Favetta

Bruna Favetta


Bruna Favetta was a Manager at CBPartners.

Connect with Bruna Favetta


Published Articles

CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?

Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.